SB 435495

Drug Profile

SB 435495

Latest Information Update: 15 Nov 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Class
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 15 Nov 2001 Discontinued-I for Atherosclerosis in USA (Unknown route)
  • 30 Apr 2001 Phase-I clinical trials for Atherosclerosis in USA (Unknown route)
  • 15 Mar 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top